These findings may in part explain the beneficial effects on hepatic fibrosis in recent phase 3 clinical trials with OCA in patients suffering from PBC and NASH and support extending clinical trials with FXR agonists to other forms of chronic liver injury51, 52. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.